Vir Biotechnology Inc. (NASDAQ:VIR) went down by -13.11% from its latest closing price compared to the recent 1-year high of $58.00. The company’s stock price has collected -14.32% of loss in the last five trading sessions. The Wall Street Journal reported on 01/11/22 that U.S. Strikes Deal for Additional Supply of Covid-19 Antibody Treatment
Is It Worth Investing in Vir Biotechnology Inc. (NASDAQ :VIR) Right Now?
Vir Biotechnology Inc. (NASDAQ:VIR) scored a price-to-earnings ratio above its average ratio, recording 4.88 x from its present earnings ratio. Opinions of the stock are interesting as 4 analysts out of 7 who provided ratings for Vir Biotechnology Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $68.67, which is $44.92 above the current price. VIR currently public float of 113.81M and currently shorts hold a 7.78% ratio of that float. Today, the average trading volume of VIR was 1.72M shares.
VIR’s Market Performance
VIR stocks went down by -14.32% for the week, with a monthly drop of -12.28% and a quarterly performance of -44.13%, while its annual performance rate touched -51.21%. The volatility ratio for the week stands at 10.12% while the volatility levels for the past 30 days are set at 7.43% for Vir Biotechnology Inc.. The simple moving average for the period of the last 20 days is -13.12% for VIR stocks with a simple moving average of -46.01% for the last 200 days.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with Robert W. Baird repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to Robert W. Baird is $28 based on the research report published on March 03rd of the current year 2022.
Robert W. Baird, on the other hand, stated in their research note that they expect to see VIR reach a price target of $36. The rating they have provided for VIR stocks is “Underperform” according to the report published on December 21st, 2021.
JP Morgan gave a rating of “Neutral” to VIR, setting the target price at $37 in the report published on October 25th of the previous year.
VIR Trading at -17.02% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.10% of loss for the given period.
Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 10.12%, as shares sank -12.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.50% lower at present.
During the last 5 trading sessions, VIR fell by -14.32%, which changed the moving average for the period of 200-days by -47.64% in comparison to the 20-day moving average, which settled at $21.82. In addition, Vir Biotechnology Inc. saw -54.43% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at VIR starting from SATO VICKI L, who sale 14,541 shares at the price of $20.62 back on May 09. After this action, SATO VICKI L now owns 1,503,463 shares of Vir Biotechnology Inc., valued at $299,835 using the latest closing price.
SATO VICKI L, the Director of Vir Biotechnology Inc., sale 17,915 shares at $20.90 during a trade that took place back on Apr 28, which means that SATO VICKI L is holding 1,518,004 shares at $374,424 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- +38.41 for the present operating margin
- +93.46 for the gross margin
The net margin for Vir Biotechnology Inc. stands at +48.25.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.58.